EA200700850A1 - Усовершенствованные аденовирусные векторы и их применение - Google Patents

Усовершенствованные аденовирусные векторы и их применение

Info

Publication number
EA200700850A1
EA200700850A1 EA200700850A EA200700850A EA200700850A1 EA 200700850 A1 EA200700850 A1 EA 200700850A1 EA 200700850 A EA200700850 A EA 200700850A EA 200700850 A EA200700850 A EA 200700850A EA 200700850 A1 EA200700850 A1 EA 200700850A1
Authority
EA
Eurasian Patent Office
Prior art keywords
adenovirus
adenovirus vectors
application
human
chimeric capsid
Prior art date
Application number
EA200700850A
Other languages
English (en)
Other versions
EA010433B1 (ru
Inventor
Мензо Янс Эмко Хавенга
Дэн Бараух
Original Assignee
Круселл Холланд Б.В.
Бет Изрейэл Диконесс Медикал Сентер Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Круселл Холланд Б.В., Бет Изрейэл Диконесс Медикал Сентер Инк. filed Critical Круселл Холланд Б.В.
Publication of EA200700850A1 publication Critical patent/EA200700850A1/ru
Publication of EA010433B1 publication Critical patent/EA010433B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10345—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
    • C12N2810/6018—Adenoviridae
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Настоящее изобретение относится к рекомбинантным аденовирусным векторам, основанным на аденовирусах, которые сталкиваются с предсуществующим иммунитетом у меньшинства популяции людей, и которые содержат химерный капсид. Химерный капсид включает волоконные белки, которые имеют, по меньшей мере, выступающий домен аденовируса человека, который связывается с рецептором коксакивируса и аденовируса (CAR), и гексонный белок из серотипа аденовируса, который сталкивается с предсуществующим иммунитетом у малой процентной доли популяции людей.
EA200700850A 2004-10-13 2005-10-12 Усовершенствованные аденовирусные векторы и их применение EA010433B1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US61846904P 2004-10-13 2004-10-13
EP04105005 2004-10-13
US69772405P 2005-07-08 2005-07-08
PCT/EP2005/055183 WO2006040330A2 (en) 2004-10-13 2005-10-12 Improved adenoviral vectors and uses thereof

Publications (2)

Publication Number Publication Date
EA200700850A1 true EA200700850A1 (ru) 2007-08-31
EA010433B1 EA010433B1 (ru) 2008-08-29

Family

ID=35945186

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200700850A EA010433B1 (ru) 2004-10-13 2005-10-12 Усовершенствованные аденовирусные векторы и их применение

Country Status (12)

Country Link
US (1) US7741099B2 (ru)
EP (1) EP1799836B1 (ru)
KR (1) KR101253363B1 (ru)
AP (1) AP2351A (ru)
AU (1) AU2005293568B2 (ru)
BR (1) BRPI0516048A (ru)
CA (1) CA2583843C (ru)
EA (1) EA010433B1 (ru)
IL (1) IL182330A (ru)
MX (1) MX2007004188A (ru)
NZ (1) NZ553889A (ru)
WO (1) WO2006040330A2 (ru)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
AU2005293568B2 (en) * 2004-10-13 2010-10-28 Beth Israel Deaconess Medical Center Inc. Improved adenoviral vectors and uses thereof
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
US7989160B2 (en) 2006-02-13 2011-08-02 Alethia Biotherapeutics Inc. Polynucleotides and polypeptide sequences involved in the process of bone remodeling
US20090110695A1 (en) * 2006-03-27 2009-04-30 Menzo Jans Emko Havenga Compositions Comprising a Recombinant Adenovirus and an Adjuvant
BRPI0813194B8 (pt) 2007-08-03 2021-05-25 Centre Nat Rech Scient kit, partículas de vetor lentiviral, composição de vetores plasmídicos, antígeno derivado de hiv-1 quimérico, proteína de envelope de vsv-g, moléculas de ácido nucleico, composição imunogênica e uso de um vetor lentiviral
WO2009065800A1 (en) * 2007-11-20 2009-05-28 Crucell Holland B.V. Recombinant human adenoviruses for eliciting mucosal immune responses
SI2340038T1 (en) 2008-10-10 2018-05-31 Children's Medical Center Corporation A biochemically stabilized HIV-1 ENV TRIMER vaccine
WO2010060719A1 (en) * 2008-11-03 2010-06-03 Crucell Holland B.V. Method for the production of adenoviral vectors
DK2358757T3 (da) 2008-11-18 2019-01-02 Beth Israel Deaconess Medical Ct Inc Antivirale vacciner med forbedret cellulær immunogenicitet
US9555089B2 (en) 2009-08-18 2017-01-31 The Rockefeller University Modification of recombinant adenovirus with immunogenic plasmodium circumsporozoite protein epitopes
KR101458367B1 (ko) * 2010-04-14 2014-11-05 재단법인 목암생명공학연구소 원숭이 아데노바이러스 혈청형 19로부터 분리된 헥손, 그의 초가변 영역 및 그를 이용한 키메라 아데노바이러스
EA029504B1 (ru) * 2010-12-14 2018-04-30 Дзе Гавермент Оф Дзе Юнайтед Стейтс Оф Америка Эз Репрезентед Бай Дзе Секретэри Оф Дзе Департмент Оф Хелт Энд Хьюмэн Сервисиз Способ индуцирования иммунного ответа против филовирусного антигена у пациента с использованием аденовирусов серотипа 26 и серотипа 35
WO2012083297A2 (en) * 2010-12-17 2012-06-21 Genvec, Inc. Adenoviral vectors with modified hexon regions
EP2654786B1 (en) 2010-12-20 2019-02-20 GenVec, Inc. Adenoviral vector-based dengue fever vaccine
CN102260712B (zh) * 2011-05-31 2013-10-02 北京锤特生物科技有限公司 溶肿瘤能力增强的B型人腺病毒Ad11突变体的构建和应用
WO2013036791A2 (en) * 2011-09-09 2013-03-14 Beth Israel Deaconess Medical Center, Inc. Modified adenoviral vectors and methods of treatment using same
US9267153B2 (en) 2011-12-15 2016-02-23 Washington University Porcine knob xenotype chimeric adenoviral vector for dendritic cell infection
MX358019B (es) * 2012-05-18 2018-08-02 Univ Pennsylvania Adenovirus de simio de la subfamilia e a1302, a1320, a1331 y a1337 y sus usos.
CA2928851A1 (en) 2012-07-19 2014-01-23 Alethia Biotherapeutics Inc. Anti-siglec-15 antibodies
KR101429696B1 (ko) 2012-11-21 2014-08-13 국립암센터 안전성 및 항암활성이 증가된 재조합 아데노바이러스 및 이의 용도
EA030983B1 (ru) 2013-01-07 2018-10-31 Бет Изрейэл Диконисс Медикал Сентер, Инк. ВАКЦИНЫ, СОДЕРЖАЩИЕ СТАБИЛИЗИРОВАННЫЕ ТРИМЕРЫ ОБОЛОЧКИ (Env) ВИРУСА ИММУНОДЕФИЦИТА ЧЕЛОВЕКА (ВИЧ), И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
KR102089121B1 (ko) 2013-03-14 2020-03-13 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 종양살상형 아데노바이러스 조성물
CN104419717B (zh) * 2013-08-23 2018-04-27 长春百克生物科技股份公司 逃避预存免疫的重组腺病毒及其构建方法和用途
WO2015051270A1 (en) 2013-10-04 2015-04-09 Beth Israel Deaconess Medical Center, Inc. Stabilized human immunodeficiency virus (hiv) clade c envelope (env) trimer vaccines and methods of using same
MX2016004579A (es) 2013-10-10 2016-12-09 Beth Israel Deaconess Medical Ct Inc Proteinas de union del miembro 1 de la familia de transmembrana 4 l-seis (tm4sf1) y metodos de uso de las mismas.
CN112121160A (zh) 2014-09-26 2020-12-25 贝斯以色列护理医疗中心有限公司 诱导针对人免疫缺陷病毒感染的保护性免疫性的方法和组合物
IL297905A (en) 2015-07-28 2023-01-01 Univ Pennsylvania Altered monocytes/macrophages expressing chimeric antigen receptors and their uses
JP7171433B2 (ja) 2015-10-30 2022-11-15 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ Ｈｅｒ－２発現固形腫瘍の処置のための組成物および方法
EP3390430B1 (en) 2015-12-15 2019-08-28 Janssen Vaccines & Prevention B.V. Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof
KR20220163505A (ko) 2016-02-23 2022-12-09 솔크 인스티튜트 포 바이올로지칼 스터디즈 바이러스 동역학에 미치는 영향 최소화를 위한 치료용 아데노바이러스의 외인성 유전자 발현
AU2017222568B2 (en) 2016-02-23 2020-09-10 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
CN109219448B (zh) 2016-06-16 2022-09-20 扬森疫苗与预防公司 Hiv疫苗配制品
US10307477B2 (en) 2016-09-02 2019-06-04 Janssen Vaccines & Prevention B.V. Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment
US10793607B2 (en) 2016-09-15 2020-10-06 Janssen Vaccines & Prevention B.V. Trimer stabilizing HIV envelope protein mutations
US11230572B2 (en) 2016-10-17 2022-01-25 Beth Israel Deaconess Medical Center, Inc. Signature-based human immunodeficiency virus (HIV) envelope (Env) trimer vaccines and methods of using the same
AU2017375633C1 (en) 2016-12-12 2023-04-27 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
KR20200015759A (ko) 2017-06-15 2020-02-12 얀센 백신스 앤드 프리벤션 비.브이. Hiv 항원을 인코딩하는 폭스바이러스 벡터, 및 그 사용 방법
EP3649237B1 (en) * 2017-07-05 2022-01-19 Nouscom AG Non human great apes adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
AU2018304502B2 (en) 2017-07-19 2022-03-31 Janssen Vaccines & Prevention B.V. Trimer stabilizing HIV envelope protein mutations
JP7438943B2 (ja) 2017-10-31 2024-02-27 ヤンセン ファッシンズ アンド プリベンション ベーフェー アデノウイルス及びその用途
MA50502A (fr) 2017-10-31 2020-09-09 Janssen Vaccines & Prevention Bv Adénovirus et utilisations associées
CN111295391B (zh) 2017-10-31 2023-12-05 扬森疫苗与预防公司 腺病毒及其用途
US11459583B2 (en) * 2017-10-31 2022-10-04 Janssen Vaccines & Prevention B.V. Adenovirus vectors and uses thereof
BR112020007884A2 (pt) 2017-11-20 2020-11-03 Janssen Pharmaceuticals, Inc. método de proporcionar uma administração segura de vetores adenovirais que codificam um antígeno de vírus zika
CA3120715A1 (en) 2018-11-21 2020-05-28 Mayo Foundation For Medical Education And Research Adenoviruses and methods for using adenoviruses
KR20210144818A (ko) 2019-04-29 2021-11-30 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 암을 치료하기 위한 다가 pd-l1 결합 화합물
CN110564768A (zh) * 2019-08-08 2019-12-13 广州佰芮慷生物科技有限公司 一种基于腺病毒HAd49的重组腺病毒表达载体及其构建方法
US20230075527A1 (en) 2020-01-31 2023-03-09 Janssen Pharmaceuticals, Inc Compositions and Methods for Preventing and Treating Coronavirus Infection - Sars-Cov-2 Vaccines
JP2023524879A (ja) 2020-05-11 2023-06-13 ヤンセン ファーマシューティカルズ，インコーポレーテッド 安定化されたコロナウイルススパイクタンパク質融合タンパク質
EP4161536A1 (en) 2020-06-04 2023-04-12 Carisma Therapeutics Inc. Novel constructs for chimeric antigen receptors
CA3188170A1 (en) 2020-06-29 2022-01-06 Janssen Vaccines & Prevention B.V. Vaccine combination against respiratory syncytial virus infection
BR112022026974A2 (pt) 2020-07-06 2023-01-24 Janssen Pharmaceuticals Inc Proteínas de fusão estabilizadas de proteínas de pico de coronavírus
WO2022084333A1 (en) 2020-10-20 2022-04-28 Janssen Vaccines & Prevention B.V. Hiv vaccine regimens
AU2022221983A1 (en) 2021-02-19 2023-08-17 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv fb antigens
WO2022175479A1 (en) 2021-02-19 2022-08-25 Janssen Vaccines & Prevention B.V. Vaccine combinations against respiratory syncytial virus strain a and b infections
AU2022249741A1 (en) 2021-04-01 2023-09-21 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion piv3 f proteins
WO2023020939A1 (en) 2021-08-17 2023-02-23 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
WO2023026182A1 (en) 2021-08-24 2023-03-02 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
WO2023047349A1 (en) 2021-09-24 2023-03-30 Janssen Pharmaceuticals, Inc. Stabilized coronavirus spike protein fusion proteins
WO2023047348A1 (en) 2021-09-24 2023-03-30 Janssen Pharmaceuticals, Inc. Stabilized corona virus spike protein fusion proteins
WO2023111725A1 (en) 2021-12-14 2023-06-22 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
WO2023110618A1 (en) 2021-12-16 2023-06-22 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion hmpv fusion proteins
EP4205759A1 (en) 2022-01-04 2023-07-05 Veterinärmedizinische Universität Wien Fowl adenovirus subunit vaccine and production method thereof
WO2023198815A1 (en) 2022-04-14 2023-10-19 Janssen Vaccines & Prevention B.V. Sequential administration of adenoviruses
WO2024061759A1 (en) 2022-09-23 2024-03-28 Janssen Vaccines & Prevention B.V. Stabilized coronavirus s proteins
WO2024061757A1 (en) 2022-09-23 2024-03-28 Janssen Vaccines & Prevention B.V. Pre-fusion human piv1 f proteins
WO2024074584A1 (en) 2022-10-06 2024-04-11 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion piv3 f proteins

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6127525A (en) 1995-02-21 2000-10-03 Cornell Research Foundation, Inc. Chimeric adenoviral coat protein and methods of using same
US5922315A (en) 1997-01-24 1999-07-13 Genetic Therapy, Inc. Adenoviruses having altered hexon proteins
US20030017138A1 (en) * 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
CA2341061A1 (en) 1998-08-27 2000-03-09 Aventis Pharma S.A. Targeted adenovirus vectors for delivery of heterologous genes
DE60014489T3 (de) * 1999-05-17 2010-08-12 Crucell Holland B.V. Von Adenovirus abgeleitete Gentransfervehikel, die zumindest ein Element des Adenovirus Typ 35 enthalten
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
JP2003530307A (ja) 1999-07-06 2003-10-14 メルク・アンド・カンパニー・インコーポレーテッド ｇａｇ遺伝子保有アデノウイルスＨＩＶワクチン
JP2004508064A (ja) 2000-09-15 2004-03-18 メルク　エンド　カムパニー　インコーポレーテッド コドン最適化ｈｉｖ１−ｇａｇ、ｐｏｌ、ｎｅｆおよび修飾体を発現する増強された第１世代アデノウイルスワクチン
EP1409012B1 (en) 2001-06-22 2009-02-11 The Wistar Institute Of Anatomy And Biology Methods of inducing a cytotoxic immune response and recombinant simian adenovirus compositions useful therein
EP1516055A4 (en) 2002-01-24 2007-08-08 Scripps Research Inst FIBER OPERATING MODIFICATIONS FOR EFFICIENT TARGETS
EP1569515A4 (en) 2002-10-23 2006-04-26 Glaxosmithkline Biolog Sa MALARIA vaccine method
WO2004037294A2 (en) 2002-10-23 2004-05-06 Crucell Holland B.V. New settings for recombinant adenoviral-based vaccines
US6921582B2 (en) * 2002-12-23 2005-07-26 General Electric Company Oxidation-resistant coatings bonded to metal substrates, and related articles and processes
WO2004083418A1 (en) 2003-03-17 2004-09-30 Merck & Co., Inc. Adenovirus serotype 24 vectors, nucleic acids and virus produced thereby
AU2005293568B2 (en) * 2004-10-13 2010-10-28 Beth Israel Deaconess Medical Center Inc. Improved adenoviral vectors and uses thereof

Also Published As

Publication number Publication date
WO2006040330A3 (en) 2006-08-24
CA2583843C (en) 2010-09-21
BRPI0516048A (pt) 2008-08-19
CA2583843A1 (en) 2006-04-20
NZ553889A (en) 2009-11-27
EA010433B1 (ru) 2008-08-29
EP1799836A2 (en) 2007-06-27
AU2005293568A1 (en) 2006-04-20
AP2007003990A0 (en) 2007-06-30
US20080199939A1 (en) 2008-08-21
KR101253363B1 (ko) 2013-04-15
AP2351A (en) 2012-01-25
IL182330A0 (en) 2007-07-24
KR20070085254A (ko) 2007-08-27
EP1799836B1 (en) 2010-12-22
WO2006040330A2 (en) 2006-04-20
IL182330A (en) 2013-02-28
MX2007004188A (es) 2007-10-11
AU2005293568B2 (en) 2010-10-28
US7741099B2 (en) 2010-06-22

Similar Documents

Publication Publication Date Title
EA200700850A1 (ru) Усовершенствованные аденовирусные векторы и их применение
ATE492643T1 (de) Verbesserte adenovirusvektoren und deren verwendung
JOP20190017A1 (ar) أجسام مضادة ترتبط مع مستقبل cgrp بشري
AU2018256592A1 (en) Binding proteins comprising at least two repeat domains against HER2
GEP20237480B (en) Antibodies against signal-regulatory protein alpha and methods of use
EA201001139A1 (ru) УЛУЧШЕННЫЕ АНТИТЕЛА АНТИ-TrkB
EA201001223A1 (ru) Стабилизированные белковые композиции
MX2012012927A (es) Composiciones y metodos de uso para anticuerpos multivalentes terapeuticos de proteina relacionada con lipoproteina de baja densidad 6 (lrp6).
SI2330197T1 (sl) Antagonistični selektivni agensi za osteoprotegerin vezavni protein
BRPI0511008A (pt) agentes de ligação de il-13
MX2007008017A (es) Polipeptidos que se ligan a br3 y usos de los mismos.
MA32190B1 (fr) Anticorps dirigés contre l'angiopoïétine 1 et l'angiopoïétine 2 et leur utilisation
EP2380592A3 (en) Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
TR201905437T4 (tr) İki işlevli polipeptidler.
WO2007051063A3 (en) Gpcr expressing cell lines and antibodies
WO2009048839A3 (en) Vaccinia virus h3l and b5r specific monoclonal antibodies and methods of making and using same
WO2008048976A3 (en) Enhancing disease resistance against rna viral infections with intracytoplasmic pathogen sensors
WO2012083297A3 (en) Adenoviral vectors with modified hexon regions
MA32770B1 (fr) Anticorps anti-peptides igf-1/e humain modifie
CO6382184A2 (es) Proteinas fijadoras de receptores de interleukinas-21
WO2010009856A3 (en) Goodpasture antigen binding protein and its detection
WO2007024668A3 (en) Targeting of herpes simplex virus to specific receptors
WO2004111251A3 (en) Modified fiber proteins for efficient receptor binding
WO2004009789A3 (en) Targeted adenoviral vector displaying immunoglobulin-binding domain and uses thereof
MA42186A1 (fr) Protéines de liaison d'antigène qui activent le récepteur de la leptine

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY RU